Verici Dx (VRCI) Competitors GBX 0.55 +0.03 (+4.76%) As of 08/15/2025 11:02 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsBuy This Stock VRCI vs. GENI, DMTR, LLAI, LLA, IDHC, DXRX, AGL, YGEN, ABDX, and PRMShould you be buying Verici Dx stock or one of its competitors? The main competitors of Verici Dx include GENinCode (GENI), Deepmatter Group (DMTR), LungLife AI (LLAI), LLA.L,0P0001T9GN,0 (LLA), Integrated Diagnostics (IDHC), Diaceutics (DXRX), ANGLE (AGL), Yourgene Health (YGEN), Abingdon Health (ABDX), and Proteome Sciences (PRM). These companies are all part of the "diagnostics & research" industry. Verici Dx vs. Its Competitors GENinCode Deepmatter Group LungLife AI LLA.L,0P0001T9GN,0 Integrated Diagnostics Diaceutics ANGLE Yourgene Health Abingdon Health Proteome Sciences Verici Dx (LON:VRCI) and GENinCode (LON:GENI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment. Do insiders & institutionals believe in VRCI or GENI? 51.9% of Verici Dx shares are owned by institutional investors. Comparatively, 47.6% of GENinCode shares are owned by institutional investors. 17.1% of Verici Dx shares are owned by company insiders. Comparatively, 39.8% of GENinCode shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media prefer VRCI or GENI? In the previous week, Verici Dx's average media sentiment score of 0.00 equaled GENinCode'saverage media sentiment score. Company Overall Sentiment Verici Dx Neutral GENinCode Neutral Which has more risk & volatility, VRCI or GENI? Verici Dx has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Comparatively, GENinCode has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Is VRCI or GENI more profitable? Verici Dx has a net margin of -110.99% compared to GENinCode's net margin of -228.70%. Verici Dx's return on equity of -71.67% beat GENinCode's return on equity.Company Net Margins Return on Equity Return on Assets Verici Dx-110.99% -71.67% -26.14% GENinCode -228.70%-289.74%-63.99% Which has better earnings and valuation, VRCI or GENI? GENinCode has lower revenue, but higher earnings than Verici Dx. GENinCode is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerici Dx£5.91M0.28-£6.56M-£1.73-0.32GENinCode£2.67M0.98-£6.10M-£3.43-0.43 SummaryVerici Dx beats GENinCode on 8 of the 11 factors compared between the two stocks. Get Verici Dx News Delivered to You Automatically Sign up to receive the latest news and ratings for VRCI and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRCI vs. The Competition Export to ExcelMetricVerici DxDiagnostics & Research IndustryMedical SectorLON ExchangeMarket Cap£1.67M£989.06M£5.74B£3.09BDividend YieldN/A5.44%3.91%5.04%P/E Ratio-0.322.2531.11174.60Price / Sales0.28473.56434.08282,733.39Price / Cash1.3111.4236.7827.94Price / Book0.122.719.085.38Net Income-£6.56M£334.07B£3.26B£5.89B7 Day Performance8.91%4.20%7.38%-0.12%1 Month Performance-45.00%2.73%4.21%0.94%1 Year Performance-91.85%3.25%30.29%66.07% Verici Dx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRCIVerici DxN/AGBX 0.55+4.8%N/A-91.9%£1.67M£5.91M-0.3219Gap DownGENIGENinCodeN/AGBX 1.55flatN/A-77.7%£2.75M£2.67M-0.452,300Gap DownHigh Trading VolumeDMTRDeepmatter GroupN/AN/AN/AN/A£1.33M£1.04M-0.11N/AGap DownLLAILungLife AIN/AGBX 3.50-17.6%N/A-73.1%£1.16M£33.87K-0.2815Gap DownHigh Trading VolumeLLALLA.L,0P0001T9GN,0N/AN/AN/AN/A£0.00N/A-25.0015Gap DownHigh Trading VolumeIDHCIntegrated DiagnosticsN/AGBX 0.38+2.7%N/A-8.7%£11.18B£23.29T14.126,692Gap UpDXRXDiaceutics2.1382 of 5 starsGBX 137.50flatGBX 175+27.3%+13.3%£116.04M£26.08M-40.78151News CoverageHigh Trading VolumeAGLANGLE1.6317 of 5 starsGBX 5.10-7.3%GBX 40+684.3%-59.2%£16.44M£2.44M-0.75650Gap DownYGENYourgene HealthN/AN/AN/AN/A£16.43M£29.67M-51.50253ABDXAbingdon HealthN/AGBX 6.53+0.4%N/A-35.1%£12.63M£3.84M-15.8784Gap DownHigh Trading VolumePRMProteome SciencesN/AGBX 2.80-7.9%N/A-34.0%£8.27M£10.88B-2.03240Gap DownHigh Trading Volume Related Companies and Tools Related Companies GENinCode Competitors Deepmatter Group Competitors LungLife AI Competitors LLA.L,0P0001T9GN,0 Competitors Integrated Diagnostics Competitors Diaceutics Competitors ANGLE Competitors Yourgene Health Competitors Abingdon Health Competitors Proteome Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:VRCI) was last updated on 8/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verici Dx plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Verici Dx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access